- Home
- JSPR vs BEAT Comparison
JSPR vs BEAT Comparison
Compare JSPR & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | BEAT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 23.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JSPR | BEAT |
|---|---|---|
| Price | $0.51 | $0.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $6.38 | $3.50 |
| AVG Volume (30 Days) | 360.0K | ★ 15.9M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.22 | 15.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,197.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.36 |
| 52 Week High | $2.51 | $4.00 |
Technical Indicators
Market Signals| Indicator | JSPR | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 44.99 |
| Support Level | $0.42 | $0.38 |
| Resistance Level | $0.67 | $0.52 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 29.43 | 8.14 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.